Michael Trotter, MD
Urology · Austin, TXNPI 1992779599
Payments from drug & device makers
Across 627 payments — averaging $1422.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$422K
- Teleflex LLC$339K
- Laborie Medical Technologies Corp.$114K
- Olympus America Inc.$14K
- Boston Scientific$877
- AbbVie$320
- plus $1K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 236 | $421,848 |
| Teleflex LLC | 289 | $339,339 |
| Laborie Medical Technologies Corp. | 11 | $114,094 |
| Olympus America Inc. | 15 | $14,207 |
| Boston Scientific | 26 | $877 |
| AbbVie(2 entities) | 14 | $320 |
| Astellas Pharma US Inc | 3 | $187 |
| Procept Biorobotics Corporation | 7 | $180 |
| Palette Life Sciences, Inc. | 1 | $109 |
| Biotissue Holdings Inc. | 1 | $71 |
| Ferring Pharmaceuticals Inc. | 3 | $70 |
| Axonics, Inc. | 2 | $62 |
| Endo USA, Inc. | 2 | $54 |
| Biogen | 1 | $53 |
| Sumitomo Pharma America, Inc. | 2 | $50 |
| Accord Healthcare, Inc. | 2 | $38 |
| Antares Pharma, Inc. | 2 | $28 |
| Telix Pharmaceuticals | 1 | $23 |
| 180 Medical, Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $21 |
| Progenics Pharmaceuticals, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Mission Pharmacal Company | 1 | $16 |
| Stimwave Technologies Incorporated | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
How this compares
$891,769 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other urology in Austin
- Varun SundaramAustin$400K
- Elizabeth MobleyAustin$283K
- Parviz KavoussiAustin$251K
- Peter RuffAustin$168K
- Zvi SchiffmanHouston$17.8M
- Jose de la CerdaSan Antonio$9M
- Daniel SaltzsteinSan Antonio$5.8M
- Jose KaramHouston$5.7M
- Daniel ZainfeldSan Antonio$4.7M
- Brian MazzarellaLakeway$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.